Literature DB >> 20727510

Medication-related problems in CKD.

Katie E Cardone1, Shaffeeulah Bacchus, Magdalene M Assimon, Amy Barton Pai, Harold J Manley.   

Abstract

Patients with CKD are often prescribed heterogeneous medications to treat disease-associated comorbidities, to slow down progression of the disease, and to minimize morbidity and mortality rates. However, the medication regimens of this population are very complex, leading to an increased potential for medication-related problems (MRPs). As kidney function declines, the type and amount of medications a patient consumes increases, thereby putting them at a higher risk for MRPs. MRPs have been known to be associated with morbidity, mortality, and a lower quality of life. This review will summarize data on the prevalence and effect of MRPs, and strategies that can be used by clinicians to reduce and resolve MRPs. 2010 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20727510     DOI: 10.1053/j.ackd.2010.06.004

Source DB:  PubMed          Journal:  Adv Chronic Kidney Dis        ISSN: 1548-5595            Impact factor:   3.620


  22 in total

1.  Contrasting Cholesterol Management Guidelines for Adults with CKD.

Authors:  Lisandro D Colantonio; Usman Baber; Maciej Banach; Rikki M Tanner; David G Warnock; Orlando M Gutiérrez; Monika M Safford; Christoph Wanner; George Howard; Paul Muntner
Journal:  J Am Soc Nephrol       Date:  2014-11-13       Impact factor: 10.121

2.  Medication reconciliation and therapy management in dialysis-dependent patients: need for a systematic approach.

Authors:  Amy Barton Pai; Katie E Cardone; Harold J Manley; Wendy L St Peter; Rachel Shaffer; Michael Somers; Rajnish Mehrotra
Journal:  Clin J Am Soc Nephrol       Date:  2013-08-29       Impact factor: 8.237

3.  Self-reported Medication Adherence and Adverse Patient Safety Events in CKD.

Authors:  Kailin L Hsu; Jeffrey C Fink; Jennifer S Ginsberg; Marni Yoffe; Min Zhan; Wanda Fink; Corinne M Woods; Clarissa J Diamantidis
Journal:  Am J Kidney Dis       Date:  2015-05-13       Impact factor: 8.860

4.  Why Nomenclature for Pharmacist-Led Interventions Matters: Conquering the State of Confusion.

Authors:  Amy Barton Pai
Journal:  Clin J Am Soc Nephrol       Date:  2018-01-02       Impact factor: 8.237

5.  Integrating a Smartphone-Based Self-Management System into Usual Care of Advanced CKD.

Authors:  Stephanie W Ong; Sarbjit V Jassal; Judith A Miller; Eveline C Porter; Joseph A Cafazzo; Emily Seto; Kevin E Thorpe; Alexander G Logan
Journal:  Clin J Am Soc Nephrol       Date:  2016-05-12       Impact factor: 8.237

Review 6.  Drug-related problem in children with chronic kidney disease.

Authors:  Norkasihan Ibrahim; Ian Ck Wong; Susan Patey; Stephen Tomlin; Manish D Sinha; Yogini Jani
Journal:  Pediatr Nephrol       Date:  2012-03-28       Impact factor: 3.714

7.  Chronic pain and analgesic use in CKD: implications for patient safety.

Authors:  Juliana Wu; Jennifer S Ginsberg; Min Zhan; Clarissa J Diamantidis; Jingjing Chen; Corinne Woods; Jeffrey C Fink
Journal:  Clin J Am Soc Nephrol       Date:  2015-02-20       Impact factor: 8.237

8.  Medication-related problems among adult chronic kidney disease patients in a sub-Saharan tertiary hospital.

Authors:  Lisper Wangeci Njeri; William Otieno Ogallo; David Gitonga Nyamu; Sylvia Adisa Opanga; Alfred Rugendo Birichi
Journal:  Int J Clin Pharm       Date:  2018-05-15

9.  Drug-related problems and its determinant among hospitalized neonates with sepsis at Jimma University Medical Center, Ethiopia: a prospective observational study.

Authors:  Mengist Awoke; Tsegaye Melaku; Mohammed Beshir
Journal:  J Pharm Health Care Sci       Date:  2021-06-01

10.  Age and diabetes mellitus associated with worse outcomes after percutaneous coronary intervention in a multi-ethnic Asian dialysis patient population.

Authors:  Jiang Ming Fam; Chun Yuan Khoo; Yee How Lau; Weng Kit Lye; Xinzhe James Cai; Lina Hui Lin Choong; John Carson Allen; Khung Keong Yeo
Journal:  Singapore Med J       Date:  2020-03-17       Impact factor: 1.858

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.